A three-sequence, three-period crossover design was used in this study. A total of 39 subjects were randomized to either Sequence 1 (n = 13) (moxifloxacin in Period 1, FOY-305 or placebo in Period 2, and FOY-305 or placebo in Period 3) , Sequence 2 (n = 13) (FOY-305 or placebo in Period 1, moxifloxacin in Period 2, and FOY-305 or placebo in Period 3) or Sequence 3 (n = 13) (FOY-305 or placebo in Period 1, FOY-305 or placebo in Period 2, and moxifloxacin in Period 3). Subjects were treated with a single oral dose of FOY-305 600 mg, placebo, or moxifloxacin 400 mg in each treatment period, with at least 4-day (approximately 96 hours) washout period between the periods.
In this study, death and serious adverse event were not reported, but an adverse reaction leading to treatment discontinuation (nausea) occurred in one subject (n = 1/39, 2.6%) in moxifloxacin group. An adverse event reported in FOY-305 group was only diarrhoea (n = 1/38, 2.6%), which was Grade 1 in severity, not serious, and recovered without treatment.
Primary endpoint:
dQTcF and ddQTcF were defined as changes in corrected QT interval using Fridericia's formula (QTcF) from baseline (QTcF value at the time of dosing in each period) and placebo-corrected dQTcF, respectively. The primary endpoint was evaluation of impact on QTcF after the administration of FOY-305 600 mg.
The mean ddQTcF in a moxifloxacin group was greater than 5 msec between at 0.67 Hours and at 24 Hours after administration and reached 14.1 msec at 3 Hours. On the other hand, the mean ddQTcF at each timepoint in a FOY-305 group was 1.58 msec at most. Additionally, a maximum dQTcF among all subjects in the FOY-305 group did not reach 10 msec within 4 hours (including timepoint at maximum plasma concentration [Cmax] of FOY-251 in each subject) after administration. The geometric mean Cmax of FOY-251 was 239 ng/mL, and the estimated mean ddQTcF (two-sided 90% confidence interval [CI]) was -1.09 (-2.12, -0.0512) msec at the Cmax. The upper limit of the two-sided 90% CI (-0.0512 msec) was below 10 msec, a standard judged as no significant effect in a QT/QTc study.
Secondary endpoint:
The secondary endpoint was pharmacokinetic (PK) parameters of plasma FOY-251 (an active metabolite of FOY-305).
When a single dose of FOY-305 600 mg was administered under fasted condition, summary statistics (mean [standard deviation] or median [minimum, maximum] only in time to maximum plasma concentration [Tmax]) of PK parameters of plasma FOY-251, were as follows: Cmax, 293 (276) ng/mL; Tmax, 1.50 (0.667, 3.00) hours; area under the plasma concentration-time curve from time zero to infinity (AUCinf), 674 (412) ng*h/mL; half-life (T1/2), 1.40 (2.13) hours; and apparent clearance (CL/F), 692 (258) L/h. The PK parameter values of plasma FOY-251 in FOY-305-02 study where a single dose of FOY-305 600 mg was administered under fasted condition in the same manner were similar to those in this study.
When the dose of FOY-305 was 600 mg, which is feasible and expected to lead to its maximum exposure in the plasma, PK parameter values of plasma FOY-251 were similar to those in FOY-305-02 study. Additionally, this study provided the information of plasma exposure that enables proper evaluation of QTc.
A single dose of FOY-305 600 mg under fasted condition showed no significant impact on QTc. FOY-305 treatment had no safety concerns and was well tolerated.
2022年08月10日
3 IPDシェアリング
有
Yes
https://www.ono.co.jp/jpnw/rd/policy.html
https://www.ono.co.jp/eng/rd/policy.html
管理的事項
研究の種別
企業治験
治験の区分
主たる治験と拡大治験のいずれにも該当しない
登録日
令和4年8月4日
jRCT番号
jRCT2071200109
1 試験等の実施体制に関する事項及び試験等を行う施設の構造設備に関する事項
(1)試験等の名称
FOY-305-03:健康成人を対象としたFOY-305のQT評価試験(COVID-19)
FOY-305-03:Thorough QT study of FOY-305 in healthy adult subjects(COVID-19)
FOY-305-03:FOY-305 TQT試験(COVID-19)
FOY-305-03:FOY-305 TQT study(COVID-19)
(2)治験責任医師等に関する事項
大澤 昌宏
Osawa Masahiro
/
小野薬品工業株式会社
Ono Pharmaceutical Co.,LTD
618-8585
/
大阪府三島郡島本町桜井3-1-1
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
0120-626-190
clinical_trial@ono.co.jp
くすり 相談室
Center Information Medical
小野薬品工業株式会社
Ono Pharmaceutical Co.,LTD
618-8585
大阪府三島郡島本町桜井3-1-1
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
0120-626-190
clinical_trial@ono.co.jp
令和3年3月19日
(3)その他の試験等に従事する者に関する事項
(4)多施設共同試験等における治験責任医師等に関する事項など
多施設共同試験等の該当の有無
なし
2 試験等の目的及び内容並びにこれに用いる医薬品等の概要
(1)試験等の目的及び内容
日本人の健康成人男性を対象にFOY-305の心電図QTに及ぼす影響を検討する。
1
実施計画の公表日
2021年04月06日
2021年04月06日
2021年04月27日
実施予定被験者数 / Sample Size
39
試験等の種類 /
Study Type
介入研究
Interventional
試験等のデザイン
Study Design
無作為化 / allocation
無作為化比較
randomized controlled trial
盲検化 /masking
二重盲検
double blind
対照 / control
プラセボ対照
placebo control
割付け / assignment
交差比較
crossover assignment
研究目的 / purpose
その他
other
プラセボの有無
あり
盲検の有無
あり
無作為化の有無
あり
保険外併用療養費の有無
実施国(日本以外) /
Countries of Recruitment(Except Japan)
なし
none
研究対象者の適格基準 / Key inclusion & exclusion criteria
主たる選択基準 / Inclusion Criteria
日本人の健康成人男性、18歳以上45歳以下、BMI 18.5以上25.0未満
Japanese healthy adult male, >=18 and <=45 of age, >=18.5 and <25.0 of BMI